ANAHEIM, CA (UroToday.com) - Spiess et al. presented two abstracts which studied the issue of prognostic risk stratification after RPLND for patients with testis cancer. The first study (#834) studied patients with metastatic non-seminomatous germ cell testis tumors who had evidence of viable germ cell tumor elements at the time of post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND).

A total of 41 patients had viable cancer at the time of PC-RPLND, with 12 patients (29%) dead of disease at a median follow-up of 3.9 years following surgery. On Cox multivariate regression analysis, intermediate and poor International Germ Cell Consensus Classification Risk Categories were associated with a poorer recurrence-free survival whereas an elevated serum alpha fetoprotein (AFP) prior to PC-RPLND and development of a post-operative recurrence were associated with poorer disease-specific survival (DSS). A cut-point for the serum AFP greater than 5.3 ng/ml was associated with a worst DSS (P = 0.0007).

( ABST [834] - Penis/Testis/Urethra: Benign and Malignant Disease (II))

UroToday.com Full Conference Reports

Written by Ashish M. Kamat, a Contributing Editor with UroToday.

Please log-in or register in order to submit comments.

Powered by AkoComment!